Seville

Az itteni vizsgálatok

Miről szól a helyszín 56 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek

• Tüdőrák14 vizsgálat
• Áttétes emlőrák7 vizsgálat
• Hólyagrák4 vizsgálat
• Krónikus vesebetegség4 vizsgálat
• 2-es típusú cukorbetegség3 vizsgálat
• Méhtestrák3 vizsgálat
• Szívelégtelenség3 vizsgálat
• Elhízás2 vizsgálat
• Hasnyálmirigyrák2 vizsgálat
• Krónikus limfoid leukémia (CLL)2 vizsgálat
• Krónikus obstruktív tüdőbetegség (COPD)2 vizsgálat
• Lupus (SLE)2 vizsgálat
• és még 20

Fázis

• 3. fázis28 vizsgálat
• 2. fázis8 vizsgálat
• 1. fázis5 vizsgálat
• 1/2. fázis3 vizsgálat
• 4. fázis3 vizsgálat
• 2/3. fázis1 vizsgálat

Állapot

• Lezárult19 vizsgálat
• Fut, nem toboroz18 vizsgálat
• Toboroz7 vizsgálat
• Még nem toboroz6 vizsgálat
• Leállították5 vizsgálat
• Visszavonták1 vizsgálat

Fő szponzor

• AstraZeneca47 vizsgálat
• Alexion Pharmaceuticals, Inc.5 vizsgálat
• MedImmune LLC2 vizsgálat
• Checkpoint Therapeutics, Inc.1 vizsgálat
• Ionis Pharmaceuticals, Inc.1 vizsgálat

Futó vizsgálatok

• Toboroz

  A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

  NCT07735637· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

  NCT07784270· 3. fázis· AstraZeneca· Forrás

• Toboroz

  An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

  NCT07720284· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

  NCT07662044· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

  NCT07667803· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

  NCT07764978· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

  NCT07430306· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain

  NCT07029737· 2. fázis· AstraZeneca· Forrás

• Toboroz

  Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

  NCT06651970· 4. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain

  NCT06764186· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain

  NCT06746116· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

  NCT06307652· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Observational Study Protocol: LIVER-R

  NCT06252753· AstraZeneca· Forrás

• Fut, nem toboroz

  Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

  NCT05771480· 3. fázis· AstraZeneca· Forrás

• Toboroz

  OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain

  NCT06068049· AstraZeneca· Forrás

• Toboroz

  PICAROS - Acalabrutinib RWE on 1L CLL in Spain

  NCT05999877· AstraZeneca· Forrás

• Fut, nem toboroz

  A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

  NCT05389449· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás

• Fut, nem toboroz

  PASS of Paediatric Patients Initiating Selumetinib

  NCT05388370· AstraZeneca· Forrás

• Fut, nem toboroz

  Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

  NCT04784715· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations

  NCT04639219· 2. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

  NCT04644068· 1/2. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

  NCT04494425· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

  NCT03819465· 1. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

  NCT03732820· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

  NCT03682068· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

  NCT03212404· 1. fázis· Checkpoint Therapeutics, Inc.· Forrás

• Fut, nem toboroz

  A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

  NCT02671435· 1/2. fázis· MedImmune LLC· Forrás

• Fut, nem toboroz

  Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

  NCT02453282· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

  NCT01933932· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

  NCT01843374· 2. fázis· MedImmune LLC· Forrás

• Fut, nem toboroz

  Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

  NCT00099437· 3. fázis· AstraZeneca· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• 2-es típusú cukorbetegség3 toboroz
• Elhízás2 toboroz
• Krónikus limfoid leukémia (CLL)2 toboroz
• Mielóma multiplex2 toboroz
• Szívelégtelenség2 toboroz
• Hólyagrák1 toboroz
• Köpenysejtes limfóma1 toboroz
• Lupus (SLE)1 toboroz
• Máj- és epeúti rák1 toboroz
• Tüdőrák1 toboroz

Lezárt vizsgálatok

• Lezárult

  AZAHAR Study To Describe Anifrolumab in a Real-World Setting

  NCT06626945· AstraZeneca· Forrás

• Lezárult

  OPTIMISE-CKD Study_current Clinical Landscape in Spain

  NCT06614712· AstraZeneca· Forrás

• Lezárult

  Real-World Outcomes in COPD Patients Starting Trixeo (Budesonide/Glycopyrronium/Formoterol) in Spain.

  NCT06321731· AstraZeneca· Forrás

• Lezárult

  A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).

  NCT06067828· 3. fázis· AstraZeneca· Forrás

• Leállították

  An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer

  NCT05592483· AstraZeneca· Forrás

• Leállították

  ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

  NCT05746559· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás

• Lezárult

  A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

  NCT05364931· 2. fázis· AstraZeneca· Forrás

• Lezárult

  Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma

  NCT05274815· 3. fázis· AstraZeneca· Forrás

• Leállították

  Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

  NCT05218096· 2. fázis· Alexion Pharmaceuticals, Inc.· Forrás

• Lezárult

  Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study

  NCT05347693· 4. fázis· AstraZeneca· Forrás

• Leállították

  Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis

  NCT04999020· 2/3. fázis· Alexion Pharmaceuticals, Inc.· Forrás

• Leállították

  A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

  NCT05056727· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

  NCT04686305· 1. fázis· AstraZeneca· Forrás

  Contact: AstraZeneca Lung Cancer Study Locator Service

• Lezárult

  Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone

  NCT04676646· 4. fázis· AstraZeneca· Forrás

• Lezárult

  Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)

  NCT04469465· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás

• Lezárult

  Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction

  NCT04610892· 2. fázis· AstraZeneca· Forrás

• Lezárult

  A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease

  NCT03976349· 1. fázis· Ionis Pharmaceuticals, Inc.· Forrás

• Lezárult

  A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

  NCT02937818· 2. fázis· AstraZeneca· Forrás

• Lezárult

  Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC

  NCT02197234· 1. fázis· AstraZeneca· Forrás

• Lezárult

  AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

  NCT02296125· 3. fázis· AstraZeneca· Forrás

• Lezárult

  AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT02151981· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

  NCT02000622· 3. fázis· AstraZeneca· Forrás

• Lezárult

  A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

  NCT02087423· 2. fázis· AstraZeneca· Forrás

• Lezárult

  AZD9291 First Time In Patients Ascending Dose Study

  NCT01802632· 1/2. fázis· AstraZeneca· Forrás

• Lezárult

  A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.

  NCT01602380· 3. fázis· AstraZeneca· Forrás